Actionable news
All posts from Actionable news
Actionable news in ONVO: ORGANOVO HLDGS INC,

Organovo Announces Initiation of Commercial Contracting for ExVive Human Kidney Tissue

SAN DIEGO, Sept. 07, 2016 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (ONVO) (“Organovo”), a three-dimensional biology company focused on delivering scientific and medical breakthroughs using its 3D bioprinting technology, today announced that it has begun commercial contracting for its second tissue service, the ExViveTM Human Kidney. This kidney proximal tubule model is a natural expansion of the Company’s preclinical product and service portfolio, allowing customers to study the effects of drug exposure on a key portion of the human kidney relevant to drug discovery and development. Organovo has already signed multiple commercial orders and is collaborating on toxicology panels and transporter studies, including with two global, top 25 pharmaceutical companies, as part of an early access program.

The ExVive Human Kidney has demonstrated important functional aspects that offer significant value in preclinical testing, including:

  • Demonstrated proximal tubule function for more than four weeks, as measured by gamma-glutamyl transferase (GGT) production;
  • Tissue-like complexity that supports the detection of injury, compensation, and recovery
  • Physiological expression of key transporters as measured by gene and protein expression, which allows for the assessment of kidney toxicity and drug:drug interactions by modeling normal tissue function;
  • Modulatable activity of key renal transporters P-gp, SGLT2, and OCT2, demonstrating a high correlation to difficult to replicate human biology;
  • Demonstrated toxicity of model kidney toxicant cisplatin, and inhibition of toxicity when blocking OCT2 function, demonstrating specific inhibition of cisplatin transport through a known transporter; and
  • Barrier function (permeability) comparable to in-vivo values, as measured by trans-epithelial electrical resistance (TEER).

“The powerful data Organovo is releasing on the ExVive Kidney Tissue demonstrates significant potential value for our pharmaceutical customers,” said Keith Murphy, chairman and CEO of Organovo. “The compelling symphony of transporter function and the...